TL;DR
This study identifies elevated levels of microRNA-193b-3p (miR-193b-3p) in the plasma of individuals with newly diagnosed Type 2 Diabetes (T2D). Further investigation reveals that this microRNA can impair glucose metabolism by targeting key proteins involved in cellular signaling and energy production, suggesting its potential as a biomarker and therapeutic target.
What Problem Does This Paper Address?
Type 2 Diabetes (T2D) is a growing global health crisis characterized by insulin resistance and pancreatic beta-cell dysfunction. While the role of microRNAs (miRNAs) in metabolic regulation is increasingly recognized, understanding the specific contributions of circulating miRNAs to T2D pathogenesis and their underlying mechanisms remains an active area of research. This paper aims to bridge this gap by investigating the differential expression of plasma miRNAs in T2D patients, exploring their potential cellular functions, and uncovering the molecular pathways they influence, particularly concerning glucose metabolism.
Methods
The researchers employed a multi-pronged approach:
- miRNA Profiling: They used miRNA microarrays to screen for differentially expressed miRNAs in plasma from T2D cases and healthy controls.
- Validation: Promising miRNA candidates were validated using TaqMan real-time quantitative PCR (qPCR) in a larger cohort.
- Proteomic Analysis: Isobaric tagging for relative and absolute quantification (iTRAQ)-based protein expression profiling was used to identify differentially expressed proteins in plasma. Multiple reaction monitoring mass spectrometry (MRM-MS) was employed for validation.
- Bioinformatic Analysis: Target prediction algorithms (miRDB, miRTarBase, TargetScan) were used to identify potential mRNA targets of the differentially expressed miRNAs. Pathway enrichment analysis (KEGG database, DAVID tools) was performed to understand the biological processes affected.
- In Vitro Studies: Human hepatoma HepG2 cells were used for transfection experiments with miR-193b-3p mimics and inhibitors to investigate its effects on cellular glucose metabolism, protein expression, and key signaling pathways (PI3K-AKT). Assays included glucose production, lactate measurements, glucose consumption, intracellular glycogen content, and Western blotting for protein analysis.
Datasets
- Plasma Samples: The study utilized plasma samples from 113 newly diagnosed, untreated T2D cases and 113 age- and sex-matched healthy controls. These were further divided into screening and validation groups.
- Microarray Data: The microarray data has been submitted to the Gene Expression Omnibus (GEO) database under accession number GSE134998.
- Proteomic Data: iTRAQ-based protein expression profiling was performed on pooled plasma samples.
Key Insights and Ideas
- miR-193b-3p as a T2D Biomarker: The consistent elevation of miR-193b-3p in T2D patients, even after adjustment for various clinical factors, strongly suggests its potential as a diagnostic biomarker for T2D.
- Impaired Glycolysis: The observed decrease in triosephosphate isomerase (TPI1), a crucial enzyme in glycolysis, in both plasma and HepG2 cells with elevated miR-193b-3p levels points towards a disruption in glucose breakdown.
- PI3K-AKT Pathway Disruption: miR-193b-3p appears to interfere with the PI3K-AKT signaling pathway by targeting YWHAZ/14-3-3ζ, which in turn influences the transcription factor FOXO1. This pathway is central to glucose homeostasis.
- Gluconeogenesis Upregulation: The study suggests that miR-193b-3p, through its effect on FOXO1, may promote gluconeogenesis (the production of glucose), potentially exacerbating hyperglycemia.
- Reduced Glucose Uptake: The inhibition of insulin receptor (IR) and GLUT2 expression by miR-193b-3p directly impacts glucose uptake into cells.
Key Results
- Plasma levels of miR-193b-3p were significantly elevated in T2D cases compared to controls (fold change = 2.01, P = 0.006).
- Plasma levels of triosephosphate isomerase (TPI1) were decreased in T2D cases (fold change = 1.37, P = 0.002).
- In HepG2 cells, transfection with miR-193b-3p mimic led to a significant decrease in TPI1 protein levels (P < 0.01).
- miR-193b-3p inhibited YWHAZ expression at both mRNA (P=0.049) and protein levels.
- Protein levels of FOXO1 and PCK1 were significantly increased in cells with elevated miR-193b-3p (P < 0.01).
- Cells with elevated miR-193b-3p showed significantly higher glucose levels in the medium after incubation in glucose-free conditions (P = 0.016).
- Elevated miR-193b-3p reduced glucose uptake and GLUT2 expression.
Limitations and Future Work
- Sample Size: The study acknowledges that the limited sample size in the screening and validation phases might have contributed to some miRNAs not being successfully measured.
- Source of miRNAs: The origin and destination of circulating miRNAs remain unclear, and further research is needed to investigate their packaging in extracellular vesicles.
- Population Applicability: The study was conducted on a middle-aged and older population, and findings may not be directly generalizable to younger individuals.
- Diabetes Diagnosis: The reliance on FPG and HbA1c for diabetes diagnosis, without oral glucose tolerance tests, could lead to misclassification.
- Experimental Conditions: An error in the experimental setup for glucose production assay (inclusion of serum) means that the observed glucose output cannot be solely attributed to gluconeogenesis.
- Cell Line Model: HepG2 cells, while commonly used, have limitations in fully representing human liver tissue. Further validation in other cell lines and in vivo models is recommended.
- Mechanism Elucidation: While the study proposes a mechanism involving YWHAZ, FOXO1, and PCK1, further experiments are needed to definitively prove this hypothesis. The exact mechanism by which miR-193b-3p affects TPI1 also requires further exploration.
- Tissue-Specific Effects: The study focused on HepG2 cells; future work should investigate the effects of miR-193b-3p on glucose metabolism in other relevant tissues like skeletal muscle and adipose tissue.
Summary updated